Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study

Graphical Abstract Sample Work

Admission biomarkers are increasingly important for risk stratification in patients with COVID-19, helping identify those at higher risk of adverse outcomes. Among these, fasting blood glucose has emerged as a simple and accessible indicator of disease severity. Although elevated glucose levels are commonly linked to diabetes mellitus, they may also occur in non-diabetic patients due to stress-induced metabolic changes during acute illness. Recent evidence suggests that higher fasting blood glucose at admission is associated with increased risk of 28-day mortality. These findings highlight the value of early metabolic assessment in guiding clinical decisions and improving patient management, though further validation is needed.

Two balance scales for two outcomes

This graphical abstract represents a multi-centre retrospective study by Wang and colleagues, published in Diabetologia in 2020, showing that fasting blood glucose (FBG) at admission independently predicted 28-day mortality in COVID-19 patients who had no previous diagnosis of diabetes. Its central visual device is a pair of weighing scales: one for 28-day mortality and one for 28-day complications. Each scale tips towards the group with higher admission glucose, so the direction of the finding is understood before a single number is read.

The figure is designed for clinicians in acute medicine, endocrinology and infectious disease, and for readers of diabetes journals scanning for clinically usable predictors.

Stress hyperglycaemia and why non-diabetic patients matter

Raised blood glucose during acute illness is not confined to people with known diabetes. Physiological stress, inflammation and some treatments can raise glucose in patients with previously normal metabolism, a phenomenon often called stress hyperglycaemia. In COVID-19, simple admission tests that flag high-risk patients early are valuable because they are cheap, widely available and do not depend on specialist assays.

By restricting the analysis to patients without a prior diabetes diagnosis, the study separates the prognostic value of admission glucose from that of established diabetes. The thresholds in the figure correspond to familiar clinical cut-offs: below 6.1 mmol/l is within the normal fasting range, while 7.0 mmol/l or above is the conventional fasting threshold used in diagnosing diabetes.

From two hospitals to two glucose groups

The top row establishes the study population and exposure. Icons of two hospitals sit beside the label "COVID-19 patients without previous diagnosis of diabetes from two hospitals". An arrow leads to two figures colour-coded by glucose group: teal for FBG below 6.1 mmol/l at admission and orange for FBG of 7.0 mmol/l or above. A SARS-CoV-2 icon in the corner anchors the disease context. These two colours are then used consistently for every result below, which removes the need for a separate key.

The figure compares only these two categories. Readers interested in intermediate glucose values or in how the authors adjusted for confounders are expected to turn to the paper, which is an appropriate division of labour between a graphical abstract and the article.

The numbers on the scales and how to read them

OutcomeFBG <6.1 mmol/lFBG ≥7.0 mmol/lEffect estimate
28-day mortality10.6%33.0%HR 2.30 (95% CI 1.49, 3.55)
28-day complications26.1%58.5%OR 3.99 (95% CI 2.71, 5.88)

The figure uses two different measures, and the distinction is worth understanding. Mortality is reported as a hazard ratio (HR), which comes from a time-to-event analysis and accounts for when deaths occurred within the 28 days. Complications are reported as an odds ratio (OR), which compares the odds of having any complication by day 28 as a binary outcome. The two are not interchangeable, and a figure that mislabels one as the other would misrepresent the analysis. Here each estimate sits directly above its scale with its confidence interval, so the measure, the size of the effect and its precision travel together.

Design choices that make the result stick

  • A familiar metaphor. The scale conveys comparison and imbalance instantly, and the pointer on each scale reinforces which side is heavier.
  • Percentages in the pans. Absolute event rates are placed in each pan, giving readers a sense of baseline risk that ratios alone do not convey.
  • Colour as the only grouping cue. Teal and orange figures recur in each pan, so the eye links rates to exposure groups without labels.
  • Full citation band. Authors, journal, volume, pages, year and DOI sit in a dark footer.

The study design, a retrospective cohort, would be reported against the STROBE statement, and the figure is consistent with that framing by describing association and prediction rather than causation.

Adapting this layout for a prognostic marker study

Studies that compare outcomes between two exposure groups suit this two-scale layout well, particularly when there are two outcomes of interest. Keep the colour coding consistent, put absolute rates beside the relative measure, and label HRs and ORs exactly as the paper does. This page is a writing sample and should not be used for clinical decision-making.

Pubrica creates figures like this through its graphical abstract service. When a prognostic study needs its survival or regression analyses checked before submission, biostatistics support is the relevant service.

Questions about this sample

Why does the figure use a hazard ratio for mortality but an odds ratio for complications?

Mortality was analysed as a time-to-event outcome, which produces a hazard ratio of 2.30. Complications were analysed as a yes-or-no outcome by day 28, which produces an odds ratio of 3.99. The figure keeps each measure with its own scale so readers do not confuse two different statistical quantities.

What glucose thresholds define the two groups?

Patients with fasting blood glucose below 6.1 mmol/l at admission form the reference group, shown in teal. Patients with 7.0 mmol/l or above form the high-glucose group, shown in orange. These cut-offs match commonly used clinical boundaries for normal fasting glucose and for the diabetes diagnostic threshold.

Why were patients with known diabetes excluded?

Excluding people with a prior diabetes diagnosis allows the study to test whether high admission glucose predicts outcomes on its own, rather than reflecting the known risks associated with established diabetes. This makes the finding relevant to stress-related hyperglycaemia in patients whose glucose metabolism was previously considered normal.

pubrica services with experts

Research your Services with our experts

Delivered on-time or your money back

Give yourself the academic edge today

Each order includes

  • On-time delivery or your money back
  • A fully qualified writer in your subject
  • In-depth proofreading by our Quality Control Team
  • 100% confidentiality, the work is never re-sold or published
  • Standard 7-day amendment period
  • A paper written to the standard ordered
  • A detailed plagiarism report
  • A comprehensive quality report

Enquire Now

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.